Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors
A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma…